Low risk patients benefit from α-IFN treatment more than high risk patients. The benefit for intermediate risk patients is less clear. The data are based on the prospective studies of the Italian Coop. Study Group on CML.65
| . | Low Risk . | High Risk . |
|---|---|---|
| Hematologic response | ≥ 90% | 40 - 60% |
| Cytogenetic response | ≥ 50% | 10 - 20% |
| Survival of responders | ≥ 10 years | 5 - 8 years |
| Relative benefit | yes | yes |
| Absolute benefit | greater | smaller |
| . | Low Risk . | High Risk . |
|---|---|---|
| Hematologic response | ≥ 90% | 40 - 60% |
| Cytogenetic response | ≥ 50% | 10 - 20% |
| Survival of responders | ≥ 10 years | 5 - 8 years |
| Relative benefit | yes | yes |
| Absolute benefit | greater | smaller |